Global Cord Blood Corp (NYSE:CO) Sees Significant Growth in Short Interest

Global Cord Blood Corp (NYSE:CO) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 70,300 shares, an increase of 32.1% from the September 30th total of 53,200 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 107,900 shares, the days-to-cover ratio is presently 0.7 days.

Several research analysts have weighed in on CO shares. ValuEngine upgraded shares of Global Cord Blood from a “hold” rating to a “buy” rating in a research note on Saturday, October 5th. TheStreet lowered shares of Global Cord Blood from a “b-” rating to a “c+” rating in a research note on Wednesday, September 4th.

Several institutional investors and hedge funds have recently made changes to their positions in CO. Campbell & CO Investment Adviser LLC acquired a new position in shares of Global Cord Blood during the 3rd quarter worth $86,000. Parametric Portfolio Associates LLC increased its stake in shares of Global Cord Blood by 20.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 94,469 shares of the medical research company’s stock worth $546,000 after purchasing an additional 15,934 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Global Cord Blood by 24.4% during the 2nd quarter. SG Americas Securities LLC now owns 134,310 shares of the medical research company’s stock worth $776,000 after purchasing an additional 26,379 shares during the last quarter. Quinn Opportunity Partners LLC increased its stake in shares of Global Cord Blood by 2.3% during the 2nd quarter. Quinn Opportunity Partners LLC now owns 259,764 shares of the medical research company’s stock worth $1,501,000 after purchasing an additional 5,800 shares during the last quarter. Finally, Man Group plc increased its stake in shares of Global Cord Blood by 28.6% during the 2nd quarter. Man Group plc now owns 899,641 shares of the medical research company’s stock worth $5,200,000 after purchasing an additional 200,000 shares during the last quarter. Institutional investors own 16.85% of the company’s stock.

Global Cord Blood stock traded down $0.02 during trading hours on Friday, hitting $4.56. The company had a trading volume of 91,100 shares, compared to its average volume of 76,756. The firm has a market capitalization of $556.70 million, a P/E ratio of 11.95 and a beta of 0.14. The firm’s fifty day moving average is $4.89 and its 200-day moving average is $5.53. Global Cord Blood has a fifty-two week low of $4.14 and a fifty-two week high of $7.73.

Global Cord Blood (NYSE:CO) last released its quarterly earnings data on Tuesday, August 27th. The medical research company reported $0.13 earnings per share for the quarter. The firm had revenue of $39.82 million for the quarter. Global Cord Blood had a net margin of 31.78% and a return on equity of 9.60%.

Global Cord Blood Company Profile

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.

Featured Article: What is an inverted yield curve?

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.